START-J: SiTAgliptin in eldeRly Trial in Japan (START-J)
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Not Applicable
Locations
Japan
Study Type
Interventional
Intervention
Sitagliptin
Glimepiride
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Type 2 Diabetes, Sitagliptin, Glimepiride, Elderly patients, Japanese
Eligibility Criteria
Inclusion Criteria:
- Patients with type 2 diabetes who are oral hypoglycemic agent naive or, α-glucosidase inhibitor or biguanide monotherapy (to be washed out 4 weeks prior to randomization)
- Signed informed consent obtained before any trial-related activities
- Treatment with diet and exercise for 12 weeks and longer at screening
- Age =>60 y.o.
- Male and Female
- HbA1c 6.9%=< <8.9%
Exclusion Criteria:
- Active proliferative retinopathy or maculopathy requiring treatment
- Liver dysfunction (>x2 of upper normal limit), moderate or severe renal dysfunction(serum Cr>1.5mg/dL in male, Cr>1.3mg/dL in female, eGFR<30), severe cardiac disease (NYHA III or IV), malignancy or uncontrolled hypertension (treated or untreated) as judged by the Investigator
- Mental incapacity (including moderate or severe dementia) precluding adequate understanding and/or cooperation as judged by the Investigator
- Recurrent hypoglycaemia or hypoglycaemic unawareness as judged by the investigator
- Previous history of severe allergy to pharmaceutical products
- Systemic glucocorticoids users or potential users
- Suspected type 1 diabetes (including slowly progressive insulin dependent diabetes mellitus) or positive anti-glutamic acid decarboxylase antibody
- Any condition that the investigator considers a potential obstacle to trial participation and/or data analysis
Sites / Locations
- Japan Association for Diabetes Education and Care
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Sitagliptin
Glimepiride
Arm Description
Outcomes
Primary Outcome Measures
Change From Baseline in HbA1c at 52 W
Number of Participants With Hypoglycaemia
Secondary Outcome Measures
The Number of Participants Achieving HbA1c < 6.9 %
Change From Baseline in HOMA-β at 52 W
β cell function is measured by the Homeostatic Model Assessment(HOMA-β). HOMA β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) - 3.5]
Change From Baseline in Insulin/Proinsulin Ratio at 52 W
Change From Baseline in Body Weight at 52 W
Full Information
NCT ID
NCT01183104
First Posted
August 16, 2010
Last Updated
March 3, 2017
Sponsor
Japan Association for Diabetes Education and Care
Collaborators
Merck Sharp & Dohme LLC
1. Study Identification
Unique Protocol Identification Number
NCT01183104
Brief Title
START-J: SiTAgliptin in eldeRly Trial in Japan
Acronym
START-J
Official Title
Efficacy and Safety Comparison of Sitagliptin and Glimepiride in Elderly Japanese Patients With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
January 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Japan Association for Diabetes Education and Care
Collaborators
Merck Sharp & Dohme LLC
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare the efficacy and the safety of sitagliptin and glimepiride in drug naïve elderly patients with Type 2 diabetes as evaluated by HbA1c change from baseline at 52 W as efficacy and incidence of hypoglycemia from randomization to 52 W as safety. The clinical hypotheses are non-inferiority of sitagliptin to glimepiride in efficacy as judged by HbA1c change from baseline at 52 W and superiority of sitagliptin to glimepiride in safety as judged by incidence of hypoglycemia in drug naïve elderly patients with T2DM. In addition, comparison of efficacy is extended to 104 W.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Type 2 Diabetes, Sitagliptin, Glimepiride, Elderly patients, Japanese
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
305 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sitagliptin
Arm Type
Experimental
Arm Title
Glimepiride
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Sitagliptin
Intervention Description
Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=< <50).
Intervention Type
Drug
Intervention Name(s)
Glimepiride
Intervention Description
Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
Primary Outcome Measure Information:
Title
Change From Baseline in HbA1c at 52 W
Time Frame
Baseline and 52 W
Title
Number of Participants With Hypoglycaemia
Time Frame
From baseline to 52 W
Secondary Outcome Measure Information:
Title
The Number of Participants Achieving HbA1c < 6.9 %
Time Frame
52 W
Title
Change From Baseline in HOMA-β at 52 W
Description
β cell function is measured by the Homeostatic Model Assessment(HOMA-β). HOMA β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) - 3.5]
Time Frame
Baseline and 52 W
Title
Change From Baseline in Insulin/Proinsulin Ratio at 52 W
Time Frame
Baseline and 52 W
Title
Change From Baseline in Body Weight at 52 W
Time Frame
Baseline and 52 W
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with type 2 diabetes who are oral hypoglycemic agent naive or, α-glucosidase inhibitor or biguanide monotherapy (to be washed out 4 weeks prior to randomization)
Signed informed consent obtained before any trial-related activities
Treatment with diet and exercise for 12 weeks and longer at screening
Age =>60 y.o.
Male and Female
HbA1c 6.9%=< <8.9%
Exclusion Criteria:
Active proliferative retinopathy or maculopathy requiring treatment
Liver dysfunction (>x2 of upper normal limit), moderate or severe renal dysfunction(serum Cr>1.5mg/dL in male, Cr>1.3mg/dL in female, eGFR<30), severe cardiac disease (NYHA III or IV), malignancy or uncontrolled hypertension (treated or untreated) as judged by the Investigator
Mental incapacity (including moderate or severe dementia) precluding adequate understanding and/or cooperation as judged by the Investigator
Recurrent hypoglycaemia or hypoglycaemic unawareness as judged by the investigator
Previous history of severe allergy to pharmaceutical products
Systemic glucocorticoids users or potential users
Suspected type 1 diabetes (including slowly progressive insulin dependent diabetes mellitus) or positive anti-glutamic acid decarboxylase antibody
Any condition that the investigator considers a potential obstacle to trial participation and/or data analysis
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yasuo Terauchi, M.D., Ph.D.
Organizational Affiliation
Yokohama City University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Japan Association for Diabetes Education and Care
City
Chiyoda-Ku
State/Province
Tokyo
ZIP/Postal Code
102-0083
Country
Japan
12. IPD Sharing Statement
Citations:
PubMed Identifier
28294488
Citation
Terauchi Y, Yamada Y, Ishida H, Ohsugi M, Kitaoka M, Satoh J, Yabe D, Shihara N, Seino Y. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged >/= 60 years (START-J trial). Diabetes Obes Metab. 2017 Aug;19(8):1188-1192. doi: 10.1111/dom.12933. Epub 2017 Apr 12.
Results Reference
derived
Links:
URL
https://www.nittokyo.or.jp/
Description
Related Info
Learn more about this trial
START-J: SiTAgliptin in eldeRly Trial in Japan
We'll reach out to this number within 24 hrs